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Summary
Chlamydiae sp. are obligate intracellular pathogens
that cause a variety of diseases in humans. Adhesion
of the infectious elementary body to the eukaryotic
host cell is a pivotal step in chlamydial pathogenesis.
Here we describe the characterization of members of
the polymorphic membrane protein family (Pmp), the
largest protein family (with up to 21 members) unique
to Chlamydiaceae. We show that yeast cells display-
ing Pmp6, Pmp20 or Pmp21 on their surfaces, or
beads coated with the recombinant proteins, adhere
to human epithelial cells. A hallmark of the Pmp
protein family is the presence of multiple repeats of
the tetrapeptide motifs FxxN and GGA(I, L, V) and
deletion analysis shows that at least two copies of
these motifs are needed for adhesion. Importantly,
pre-treatment of human cells with recombinant Pmp6,
Pmp20 or Pmp21 protein reduces infectivity upon
subsequent challenge with Chlamydia pneumoniae
and correlates with diminished attachment of
Chlamydiae to target cells. Antibodies speciﬁc for
Pmp21 can neutralize infection in vitro. Finally, a com-
bination of two different Pmp proteins in infection
blockage experiments shows additive effects, possi-
bly suggesting similar functions. Our ﬁndings imply
that Pmp6, Pmp20 and Pmp21 act as adhesins, are
vital during infection and thus represent promising
vaccine candidates.
Introduction
Chlamydiae are Gram-negative bacteria with compact
genomes, and some species represent signiﬁcant threats
to human health. Chlamydia trachomatis is the most
prevalent sexually transmitted bacterial pathogen world-
wide (Schachter, 1999). Chlamydia pneumoniae is an
important respiratory pathogen, causing pneumonia and
bronchitis, and is associated with several chronic dis-
eases (Schachter, 1999). Despite the clinical relevance of
Chlamydia, no vaccine is available for use in humans
(Brunham and Rey-Ladino, 2005; Puolakkainen, 2009).
Chlamydia species have a unique biphasic developmen-
tal cycle, alternating between the infectious elementary
body (EB) and the metabolically active, intracellular reticu-
late body (RB) that replicates in eukaryotic cells (for
reviews see Moulder, 1991; Hatch, 1999). The mecha-
nisms underlying EB infectivity are unclear (Campbell and
Kuo, 2006; Scidmore, 2006).
Polymorphic membrane proteins (Pmps) found in
species of the Chlamydiaceae are candidate adhesins
(Longbottom et al., 1998; Stephens et al., 1998; Grim-
wood and Stephens, 1999; Kalman et al., 1999;
Knudsen et al., 1999; Read et al., 2003; Wehrl et al.,
2004; Crane et al., 2006). The C. trachomatis pmp gene
family has nine members (Stephens et al., 1998; Grim-
wood and Stephens, 1999; Tan et al., 2006), represent-
ing six subtypes: A, B/C, D, E, G and H. C. pneumoniae
has 21 pmp genes, 13 of which (pmp1–pmp13) belong
to subtype G (Grimwood and Stephens, 1999; Kalman
et al., 1999). The pmp genes make up more than 5% of
the total coding capacity of the genome, and are unique
to the Chlamydiaceae, suggesting that their products
might be virulence factors (Horn et al., 2004). The
various Pmp families show little similarity in amino acid
sequence, but all members contain multiple repeats
of the motifs GGA(I, L, V) and FxxN (Grimwood and
Stephens, 1999; Rockey et al., 2000). The GGAI
sequence is predicted to be present in only 10 other
proteins (and only in one copy per protein) in the
chlamydial proteomes, underscoring the over-
representation of the motif in the Pmp families (Grim-
wood and Stephens, 1999). Similarly, the FxxN motif is
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© 2010 Blackwell Publishing Ltdfound on average 13.6 times per Pmp protein in C. tra-
chomatis and 11.3 times in C. pneumoniae, respectively,
while its average incidence in the rest of the proteome is
0.73 (C. trachomatis) or 0.84 (C. pneumoniae) (Grim-
wood and Stephens, 1999).
Pmp proteins resemble classical autotransporters
(ATs), with (i) an N-terminal sequence for sec-dependent
translocation across of the cytoplasmic membrane,
(ii) a C-terminal b-barrel domain with a phenylalanine
at the end suggestive for a outer membrane localization
of Pmp proteins, and (iii) a central passenger domain
(PD) responsible for the protein’s function that can
remain surface-localized or be secreted (e.g. Pmp21 in
Fig. 1A) (Henderson and Lam, 2001; Dautin and Bern-
stein, 2007; Wells et al., 2007). The Pmp PDs, which
carry nearly exclusively the tetrapeptide repeats, prob-
ably adopt a parallel b-helix structure (Vandahl et al.,
2002). Like other AT proteins, Pmps apparently undergo
proteolytic processing (e.g. Pmp21 in Fig. 1B) (Vandahl
et al., 2001; 2002; Vretou et al., 2003; Wehrl et al., 2004;
Kiselev et al., 2009; Swanson et al., 2009). However,
there is no evidence for secretion of Pmps by the AT
pathway.
Some Pmps are known to be surface-located on infec-
tious EBs, and are thus positioned at the interface
between pathogen and the infected cell (Vandahl et al.,
2002; Wehrl et al., 2004; Crane et al., 2006; Kiselev
et al., 2009; Swanson et al., 2009). Antibodies against
Pmp21 from C. pneumoniae or PmpD from C. trachoma-
tis inhibit infection in vitro (Wehrl et al., 2004; Crane
et al., 2006). Patients infected with either species show
signiﬁcant serological responses to various Pmps (Bunk
et al., 2008; Tan et al., 2009). The high degree of varia-
tion found among pmp gene families suggests that they
are under selective pressure (Grimwood and Stephens,
1999; Shirai et al., 2000; Pedersen et al., 2001; Rocha
et al., 2002; Gomes et al., 2005; 2006; Tan et al., 2009).
Indeed, C. trachomatis inclusions formed in cultured
cells exhibit variability in the sets of Pmps they express,
suggesting they confer antigenic diversity (Tan et al.,
2010).
We show that Pmp6, Pmp20 and Pmp21, represent-
ing three of the six subtypes (B/C, D, G), act as adhes-
ins during infection by C. pneumoniae. FxxN and
GGA(I, L, V) motifs are necessary for this activity.
Pmp21 has several adhesive domains, but the strongest
cell-binding and infection-blocking activities are associ-
ated with processed forms of the protein known to occur
in vivo. A 32-residue Pmp21 peptide including a FxxN/
GGAV doublet can competitively reduce a C. pneumo-
niae infection. Interestingly, a combination of two
different Pmp proteins in infection blockage experiments
shows additive effects, possibly suggesting similar
functions.
Results
C. pneumoniae Pmp21 mediates adhesion to human
epithelial cells
Pmp21 and PmpD from C. trachomatis are targets of
neutralizing antibodies and may function in pathogenesis
(Wehrl et al., 2004; Crane et al., 2006). To ask if Pmp21 is
an adhesin, we used a yeast display system (Fig. S1)
(Moelleken and Hegemann, 2008). The PD of Pmp21
(residues 30–1144) (Fig. 1C) was fused to the yeast
surface protein Aga2p (Aga2–Pmp21-PD) and the cells
were tested for adhesion to human epithelial HEp-2 cells.
Yeast cells displaying Aga2–Pmp21-PD, but not Aga2
alone or Aga2 fused to the chlamydial outer membrane
protein OmpA (MOMP), adhered to HEp-2 cells (Fig. 1D;
Fig. S2). Indeed, cells displaying Pmp21-PD showed
signiﬁcantly stronger adhesion to HEp-2 cells than did
cells presenting Yersinia pseudotuberculosis invasin
(Aga2–Inv197) or chlamydial OmcB (Fig. 1E) (Dersch and
Isberg, 1999; Moelleken and Hegemann, 2008). Thus,
Pmp21-PD can mediate adhesion to human cells.
Several domains of Pmp21 can mediate adhesion to
HEp-2 cells
ToidentifythepartsofC.pneumoniaePmp21thatmediate
binding, we tested four subdomains of Pmp21-PD in the
yeast system (Fig. 1C). Any one of them fused to Aga2
mediated adherence to HEp-2 cells, although all were less
effective than Pmp21-PD (Fig. 1F).
We also performed latex bead assays with Pmp21
(Dersch and Isberg, 1999). We puriﬁed Pmp21-PD and
the four Pmp21 domains A–D, expressed as His-tagged
proteins in Escherichia coli, and incubated them with
latex beads. The coated beads were then tested for
adhesion to HEp-2 cells. Beads loaded with recombinant
MBP or MBP-OmpA or BSA exhibited scarcely any
binding to HEp-2 cells, while beads bearing His- or
MBP-tagged invasin or Pmp21-PD (or any of its four
fragments) clearly bound to human cells (Fig. 1G;
Fig. S2). Thus, Pmp21-PD has several independent
binding domains that mediate adherence to human cells.
Published work suggests that Pmp21 is cleaved in vivo,
and infectious EBs probably carry at least three different
processed forms (N-Pmp21, M-Pmp21 and C-Pmp21)
(Fig. 1B). The last, comprising the b-barrel unit, probably
remains in the outer membrane (Grimwood et al., 2001;
Vandahl et al., 2002; Wehrl et al., 2004). We created two
variants, Pmp21-E and Pmp21-G, corresponding to
N-Pmp21 and M-Pmp21 respectively (Fig. 1C). Latex
beads coated with either adhered to HEp-2 cells just as
well as the other Pmp21 variants tested (Fig. 1G). Thus,
the processed N-Pmp21 and M-Pmp21 forms found on
EBs can bind to human cells.
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tetrapeptide motifs
The only feature common to the variants tested so far is
the presence of repeated GGA(I, L, V) and FxxN motifs
(Fig. 1C). We selected Pmp21-B and Pmp21-D, which
showed comparable adhesion properties in the yeast
assay, but have very different numbers of tetrapeptide
repeats (Fig. 2), for further study. Deletion experiments
revealed that the 50-residue Pmp21-BD2, with one FxxN
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contrast, N-terminal truncation of Pmp21-D, deleting the
only two tetrapeptide FxxN motifs present, resulted in a
signiﬁcant reduction (Pmp21-DD1) or complete loss
(Pmp21-DD2) of adhesiveness (Fig. 2). Thus Pmp21
domains with two FxxN motifs (Pmp21-D) and one FxxN
and two GGA(I, V, L) motifs (Pmp21-BD2) both show
signiﬁcant adhesion to HEp-2 cells.
To conﬁrm that these motifs are necessary for Pmp21-
mediated adhesion to human cells, we chose Pmp21-A
and Pmp21-D (Fig. 3A). We mutated the FYKN motif in
Pmp21-A to SYKV, leaving the GGAV motif unchanged.
Beads bearing Pmp21-A-mut1 exhibited no adhesion to
human cells. Similarly, deletion of the GGAV motif in
Pmp21-A, leaving the FYKN motif intact, abrogated adhe-
sion (Pmp21-A-mut2, Fig. 3A and B). In Pmp21-D we
changed a single residue in the N-terminal FYGN motif,
keeping the FEGN motif intact, or changed both motifs.All
three mutant forms of Pmp21-D showed no adhesive
capacity (Fig. 3A and C). Hence the FxxN and GGAV
motifs are necessary for binding of the Pmp21A and
Pmp21D domains to HEp-2 cells. A minimum of two
copies of either motif (FxxN + GGAV or FxxN + FxxN) is
required for adhesion.
C. pneumoniae Pmp21 is located on the surface of EBs
and RBs during infection
Thus far our data indicate that Pmp21-PD on yeast cells
or latex beads can bind human cells. Next we analysed
the localization of Pmp21 on infectious EBs. Anti-
Pmp21-D antibody speciﬁcally detects a 55–60 kDa
protein in lysates of HEp-2 cells infected with C. pneu-
moniae prepared 36–96 h post infection (p.i.). This prob-
ably corresponds to the processed M-Pmp21 identiﬁed
previously in RBs (Fig. 4A) (Wehrl et al., 2004). The high
levels found at 96 h p.i. suggested that this form might
be present in EBs and, indeed, a strong M-Pmp21 signal
was observed in extracts of EBs (Fig. 4B). In EB
extracts containing Sarkosyl and DTT, additional weak
bands were detected: one of > 170 kDa corresponding
to the full-length N/M/C-Pmp21 and one of > 130 kDa –
probably N/M-Pmp21 (Fig. 4B). This pattern has been
described for Pmp21 isolated 4 days p.i. (Wehrl et al.,
2004).
Indirect immunoﬂuorescence microscopy of infected
cells revealed that Pmp21 can be detected in the
chlamydial inclusion and colocalizes with the bacteria at
all times analysed. As the C. pneumoniae inclusions are
Fig. 1. Pmp21 mediates adherence to human cells.
A. Schematic representation of Pmp21. The full-length protein is depicted at the top, with the N-terminal signal sequence (SS) and the
C-terminal b-barrel domain (b-barrel). Each of the tetrapeptide motifs GGA(I, L, V) and FxxN in the central passenger domain is marked. Two
known proteolytic cleavage sites in Pmp21 are indicated by arrows (Vandahl et al., 2002; Wehrl et al., 2004).
B. Processed forms of Pmp21 detected by proteome analysis (Grimwood et al., 2001; Vandahl et al., 2002; Wehrl et al., 2004).
C. The Pmp21 passenger domain (Pmp21-PD) and its subdomains Pmp21-A to -G studied in this work.
D. Micrographs of HEp-2 cells incubated with yeast cells expressing the indicated proteins. Bar 10 mm (see also Fig. S1).
E. Binding of yeast cells expressing Aga2, Aga2–Inv197, Aga2–OmcB and Aga2–Pmp21-PD to HEp-2 cells (see also Fig. S2).
F. Binding of yeast cells expressing Aga2, Aga2–Inv197, Aga2–Pmp21-PD, Aga2–Pmp21-A, -B, -C and -D to HEp-2 cells.
G. Adhesion of latex beads coated with the indicated proteins to HEp-2 cells. Beads (1 ¥ 10
6) coated with 100 mg BSA, rPmp21-PD,
rPmp21-A, -B, -C, -D, -E and -G were incubated with 1 ¥ 10
5 HEp-2 cells and the number of beads associated with HEp-2 cells was
determined by microscopy.
The data in (E)–(G) are based on the inspection of 1000 HEp-2 cells per experiment, and the results for each construct are derived from four
independent experiments. Error bars indicate standard deviations.
Fig. 2. Identiﬁcation of minimal Pmp21
adhesion domains. Schematic representation
of the deletion variants generated in the
Pmp21-B and Pmp21-D domains, and
summary of their relative adhesion activities
when expressed as Aga2 fusions on yeast
cells. The position of each of the tetrapeptide
motifs GGA(I, L, V) and FxxN is marked. The
relative binding affinity of yeast cells
expressing each Pmp21 deletion variant for
HEp-2 cells is indicated on the right, and is
expressed as the number of yeast cells
bearing the indicated constructs found
adhering to 1000 HEp-2 cells. Adhesion was
quantiﬁed as explained in the legend to Fig. 1.
SD, standard deviation.
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inclusion lumen for possible Pmp21 signals not associ-
ated with bacteria. This had been reported for the C.
trachomatis homologue PmpD (Kiselev et al., 2009;
Swanson et al., 2009). The Pmp21 staining pattern did
not change signiﬁcantly over the course of the infection.
Pmp21 was never found outside the inclusion
(Fig. S3A). Next we analysed the localization of Pmp21
in greater detail. HEp-2 cells infected with C. pneumo-
niae were ﬁxed with methanol or formaldehyde 48 h p.i.,
and incubated with the anti-Pmp21-E and an antibody
against either the intrachlamydial DnaK or the extra-
chlamydial OmpA. In methanol-ﬁxed cells, all antibodies
reacted with the bacteria in the inclusion. Anti-OmpA
antibody, which stains the chlamydial surface, colocal-
ized with anti-Pmp21, giving a ring-like signal (Fig. 4D).
In formaldehyde-ﬁxed cells intracytoplasmic proteins are
inaccessible to antibodies (the anti-DnaK antibody gave
only a very weak signal), while both the anti-OmpA and
anti-Pmp21 antibodies reacted, indicating that their
targets are located on the bacterial surface (Fig. 4C,
PFA; Fig. S3C). At higher magniﬁcation in formaldehyde-
ﬁxed cells, a dotted ring-like pattern surrounding the
DAPI signals representing the bacteria was generated
by the anti-Pmp21 antibodies (Fig. 4E; white arrows
mark single Pmp21 signals). Microimmunoﬂuorescence
of viable, unﬁxed C. pneumoniae EBs conﬁrmed that
OmpA and Pmp21 were localized on the bacterial cell
surface, while DnaK was only rarely accessible
(Fig. S3B).
Fig. 3. Mutational analysis of Pmp21
adhesion domains.
A. Schematic representation of the alterations
introduced into Pmp21-A and Pmp21-D (see
Fig. 1C). The position and speciﬁc sequence
of each of the tetrapeptide motifs GGA(I, L, V)
and FxxN are depicted.
B and C. Binding of latex beads (1 ¥ 10
6)
coated with the indicated recombinant Pmp21
variants to 1 ¥ 10
5 HEp-2 cells. For details,
see the legend to Fig. 1.
Fig. 4. C. pneumoniae Pmp21 is expressed on the bacterial surface during infection.
A. Pmp21 expression was assessed by immunoblot analysis with anti-Pmp21-D using lysates from HEp-2 cells infected with C. pneumoniae
GiD at moi 1 for 12–96 h. The host marker actin was used as loading control.
B. Immunoblot analysis of total protein lysates prepared from gradient-puriﬁed EBs. EBs (~10
7) were resuspended in PBS or in PBS
containing 2% SDS, 2% sarcosyl and 10 mM DTT for 30 min at 37°C, and analysed by SDS-PAGE using anti-Pmp21-D serum
(antigen-puriﬁed). Band 1 corresponds in size to N/M/C-Pmp21, band 2 to the processing intermediate N/M-Pmp21 and band 3 to the fully
processed M-Pmp21 form. A star marks an unspeciﬁc cross-reacting band seen in uninfected HEp-2 cells and in EBs puriﬁed from infected
HEp-2 cells.
C. Localization of Pmp21 during infection. HEp-2 cells were infected with C. pneumoniae for 48 h, and ﬁxed with methanol (methanol) for
visualization of intra- and extrachlamydial antigens. Antibodies directed against DnaK, OmpA and Pmp21 detected chlamydial particles in the
inclusion. Fixation with formaldehyde (PFA) and permeabilization with 0.5% Triton X-100 allowed visualization of extrachlamydial antigens
(Birkelund et al., 1990). Bar 5 mm.
D. Higher magniﬁcation of inclusions seen in methanol-ﬁxed cells 48 h post infection with C. pneumoniae. Antibodies directed against OmpA
(red) and Pmp21 (green) detect chlamydial particles in the inclusion. Note the ring-shaped patterns often seen upon labelling of OmpA and
Pmp21. Bar 1 mm.
E. Higher magniﬁcation of inclusions seen in formaldehyde/Triton X-100-ﬁxed cells 48 h post infection. Antibodies directed against Pmp21
(green) detect chlamydial particles in the inclusion, which were counterstained with DAPI. Note the dotted ring-shaped patterns often seen
upon labelling of Pmp21 (marked by white arrows). Bar 1 mm (see also Fig. S3).
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© 2010 Blackwell Publishing Ltd, Molecular Microbiology, 78, 1004–1017Pmp21 is required for infection of HEp-2 cells by
C. pneumoniae
We then tested directly whether Pmp21 on the EB surface
is needed for chlamydial attachment to host cells. Incu-
bation of puriﬁed EBs with anti-Pmp21 reduced infectivity
of C. pneumoniae by up to 80%; while incubation with
pre-immune serum only reduced infection by 35%
(Fig. 5A). We then blocked Pmp21 binding sites on
human cells by pre-incubation of HEp-2 cells with
Pmp21-PD and again found strong (~90%) inhibition of
infection by C. pneumoniae EBs (Fig. 5B). Pre-incubation
with the individual Pmp21 domains shown to bind to
HEp-2 cells also reduced infection rates. Pmp21-E and
Pmp21-G, which resemble the naturally occurring pro-
cessed forms N-Pmp21 and M-Pmp21 (see Fig. 1B and
C), inhibited subsequent infection by ~40% (Fig. 5B). Fur-
thermore, binding of infectious EBs stained with the ﬂuo-
rescent dye CFSE to HEp-2 cells was dose-dependently
reduced by up to 90% following pre-incubation with
Pmp21-PD (Fig. 5C). Taken together, these results dem-
onstrate that EB-associated Pmp21 mediates adhesion of
Fig. 5. Recombinant Pmp21 inhibits infection by C. pneumoniae. Infection of HEp-2 cells by C. pneumoniae is inhibited by prior addition of
anti-Pmp21, recombinant Pmp21 or a synthetic peptide derived from Pmp21.
A. Puriﬁed EBs were incubated with PBS, pre-immune serum (diluted 1:1 with PBS) or serially diluted anti-Pmp21-E before being used for
infection of HEp-2 cells. The number of inclusions formed was determined by microscopy 48 h p.i. The data in (A), (B) and (D) are derived
from four independent experiments for each condition, each involving observation of 20 microscope ﬁelds.
B. HEp-2 cells (1 ¥ 10
6) were incubated with PBS, 200 mgm l
-1 BSA, or 100 mgm l
-1 or 200 mgm l
-1 recombinant Pmp21-PD or one of the other
Pmp21 variants as indicated prior to incubation with puriﬁed C. pneumoniae EBs. Cells were ﬁxed 48 h p.i. and the number of inclusions
determined as explained above. PBS control = 100%.
C. Adhesion of viable, CFSE-stained C. pneumoniae EBs to human HEp-2 cells was detected by ﬂow cytometry. Attachment of EBs in the
presence of PBS or 200 mgm l
-1 BSA served as the control, and the ﬂuorescence intensity associated with HEp-2 cells pre-incubated in PBS
was set to 100%. Binding of EBs in the presence of 500 U ml
-1 heparin or increasing amounts of recombinant Pmp21-PD were analysed
accordingly. n = 2 wells; number of experiments = 6. Error bars indicate standard deviations.
D. A Pmp21-derived peptide attenuates C. pneumoniae infection. Prior to incubation with puriﬁed C. pneumoniae EBs, HEp-2 cells (1 ¥ 10
6)
were incubated without or with increasing amounts (1.7–54.4 mgm l
-1) of a 32-amino-acid peptide derived from Pmp21 (residues 745–776)
(peptide) or a scrambled version of the sequence with the same amino acid composition (scrambled peptide). Cells were ﬁxed 48 h p.i. and
the number of inclusions determined by microscopy as detailed above. PBS control = 100%.
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process.
A synthetic peptide derived from Pmp21 attenuates
a C. pneumoniae infection
Finally, we asked if a peptide containing a typical tetrapep-
tide motif doublet derived from Pmp21 could block EB
binding and reduce infectivity. We chose the sequence
between positions 745 and 776 in M-Pmp21, which has
an N-terminal FSDN and a C-terminal GGAI motif. Pre-
incubation of HEp-2 cells with the synthetic peptide inhib-
ited infection by C. pneumoniae by up to 40%, while a
scrambled peptide had no effect (Fig. 5D). This result
underlines the importance of the tetrapeptide motifs for
Pmp21 function in C. pneumoniae infections.
Pmp6 and Pmp20 mediate attachment of infectious
C. pneumoniae EBs to human cells
Pmp21 is one of 21 Pmps in C. pneumoniae. To ask
whether other subtypes are relevant for C. pneumoniae
infections, we chose Pmp6 (subtype B/C) and Pmp20 (G),
which resemble Pmp21 (D) in length and in possessing
> 30 tetrapeptide motifs in their N-terminal and central
regions (Fig. 6A). Fluorescent beads coated with rPmp6-1
or rPmp20-1 adhered more strongly to epithelial cells than
beads coated with rPmp21-E or invasin (Fig. 6B). Consis-
tent with this, binding of viable, ﬂuorescently labelled
infectious EBs to HEp-2 cells was signiﬁcantly reduced
when the human cells were pre-incubated with
200 mgm l -1 rPmp6-1 or rPmp20-1 (Fig. 6C). Recombi-
nant Pmp21-E had a similar effect, conﬁrming the result
obtained for the Pmp21 full-length passenger domain
Pmp21-PD (see Fig. 5C). Thus, our ﬁndings imply that
Pmp6, Pmp20 and Pmp21 all contribute to adhesion of C.
pneumoniae EBs to target cells.
Pmp6, Pmp20 and Pmp21 are important for infection
and exhibit additive effects
Thus far the results obtained for rPmp6 and rPmp20 par-
allel those obtained for Pmp21. We therefore tested
whether Pmp6 or Pmp20 are also relevant for the chlamy-
Fig. 6. Pmp6, Pmp20 and Pmp21 carry
multiple repeats of both tetrapeptide motifs,
adhere to HEp-2 cells and are important for
infection.
A. Schematic representation of the Pmp6,
Pmp20 and Pmp21 proteins from C.
pneumoniae, together with the protein
domains analysed here. The position of each
of the tetrapeptide motifs GGA(I, L, V) and
FxxN is marked and the total number of each
motif type found is given on the right.
B. Adhesion of Pmp6- or Pmp20-coated
ﬂuorescent latex beads to HEp-2 cells. Green
ﬂuorescent beads (1 ¥ 10
7) were coated with
(200 mgm l
-1) BSA, recombinant Inv497 (rInv497),
rPmp6-1, rPmp20-1 or rPmp21-E, and
incubated with 1 ¥ 10
6 HEp-2 cells. Mean
ﬂuorescence of HEp-2 cells was determined
by ﬂow cytometric analysis. (1 ¥ 10
6 HEp-2
cells per sample). Data are based on four
independent experiments for each protein.
C. Adhesion of viable, CFSE-stained C.
pneumoniae EBs to human HEp-2 cells is
reduced in the presence of rPmp6, rPmp20 or
rPmp21. The ﬂuorescence intensity
associated with attachment of EBs to HEp-2
cells in the presence of PBS served as the
control and was set to 100%. Data are based
on two independent experiments, each
performed in triplicate (n = 6). Error bars
indicate standard deviations.
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nant Pmp6 or Pmp20 inhibited subsequent infection by
the bacteria in a dose-dependent manner (Fig. 7A). The
kinetics of Pmp20- and Pmp21-induced inhibition of infec-
tion are very similar, but differ from the results for Pmp6.
Nevertheless, these data show that Pmp6 and Pmp20
contribute to EB adhesion and to subsequent C. pneumo-
niae infection.
The data obtained for the three Pmp proteins suggest
that the proteins might have overlapping functions. We
therefore combined two different Pmp proteins in a
single infection blockage experiment. Human cells were
pre-incubated with either rPmp6-1 or rPmp21-E protein
alone, or a combination of both. Pre-treatment of human
cells with 25 mgm l -1 rPmp6-1 or rPmp21-E did not
reduce infection (106% and 103% of the control values
respectively). Interestingly, the combination of 25 mgm l -1
rPmp21-E and 25 mgm l -1 rPmp6-1 signiﬁcantly reduced
subsequent infection to 87% (P-value: 0.001), and
50 mgm l -1 rPmp21-E reduced it further (80%), while
50 mgm l -1 rPmp6-1 had no effect (102%). These data
suggest that soluble rPmp6-1 and rPmp21-E additively
inhibit infection, suggesting some overlap in the
functions of the native proteins during a chlamydial
infection.
Discussion
Successful infection of host cells depends on a battery of
virulence factors, including specialized bacterial surface
structures which mediate uptake by host cells (Carbon-
nelle et al., 2009; Kline et al., 2009). Chlamydiae enter
cells via multiple routes, using poorly understood mecha-
nisms (Campbell and Kuo, 2006). In this study we show
that Pmp6, Pmp20 and Pmp21 act as adhesins during
infection of human cells by C. pneumoniae.
Pmps exhibit characteristic features of autotransport-
ers, including proteolytic processing (Grimwood and
Stephens, 1999; Henderson and Lam, 2001). Pmp21, like
its C. trachomatis homologue PmpD, is processed during
infection, and processed forms of Pmp6 and Pmp20 have
been identiﬁed in puriﬁed EBs (Vandahl et al., 2002;
Wehrl et al., 2004; Kiselev et al., 2009; Swanson et al.,
2009). Full-length Pmp21 (N/M/C-Pmp21), the intermedi-
ate N/M-Pmp21 and the fully processed N-Pmp21 were
detected during infection and in infectious EBs, while pro-
teome studies of EBs identiﬁed the putative end-products
of processing, N-Pmp21, M-Pmp21 and the translocator
unit C-Pmp21 (Fig. 1B) (Vandahl et al., 2002; Wehrl et al.,
2004). Using antibodies against the C-terminal part of the
PD we detected a protein corresponding in size to the fully
Fig. 7. Pmp6, Pmp20 and Pmp21 are
important for infection and exhibit additive
effects.
A. C. pneumoniae infection is inhibited by
pre-incubation with recombinant Pmp6-1 or
Pmp20-1. HEp-2 cells (1 ¥ 10
6) were
incubated with PBS or with different
concentrations of recombinant Pmp6-1 or
recombinant Pmp20-1 (12.5–200 mgm l
-1) prior
to infection with puriﬁed C. pneumoniae EBs.
Cells were ﬁxed 48 h p.i., and the number of
inclusions was determined by microscopy
(see legend to Fig. 4 for details). PBS
control = 100%. Number of experiments = 4.
Error bars indicate standard deviations.
B. The infection inhibition assay described in
(A) was repeated using a mixture of
recombinant Pmp6-1 and rPmp21-E. HEp-2
cells (1 ¥ 10
6) were incubated prior to
infection with puriﬁed C. pneumoniae EBs
with 25 mgm l
-1 or 50 mgm l
-1 rPmp6-1 or
rPmp21-E alone or a mixture comprising
25 mgm l
-1 each of rPmp21-E and rPmp6-1.
The experiment was otherwise performed as
described in (A). PBS control = 100%.
***P-value of 0.001.
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and on EBs (Fig. 4). Indeed, it appears that the majority of
Pmp21 is fully processed during infection, resulting in
N-Pmp21 (Wehrl et al., 2004), M-Pmp21 (this work) and
presumably C-Pmp21 as well. N- and M-Pmp21 remain
associated with the bacterial cell surface throughout infec-
tion (Fig. 4; Fig. S3) (Wehrl et al., 2004). This differs from
the more complex set of processed forms described for
the homologous PmpD protein from C. trachomatis
(Kiselev et al., 2009; Swanson et al., 2009).
Our data show that M-Pmp21 colocalizes with the outer
membrane protein OmpA (MOMP), conﬁrming other
Pmp21 localization studies (Vandahl et al., 2002; Wehrl
et al., 2004). Interestingly, our anti-Pmp21-E antibody
detected dotted, ring-like structures associated with the
bacterial cell surface (Fig. 4E). It remains to be seen
whether these dots correspond to the oligomeric struc-
tures observed for PmpD (Swanson et al., 2009). Pmp6
and Pmp20 are also found associated with the bacterial
cell surface (Montigiani et al., 2002; Vandahl et al., 2002).
As with Pmp21, the adhesive and infection-relevant prop-
erties of Pmp6 and Pmp20 described here were found to
reside in their N-terminal segments.
Our studies show that Pmp21-PD (essentially equiva-
lent to N/M-Pmp21), Pmp21-G and Pmp21-E (similar to
N- and M-Pmp21 respectively) retain adhesive capacities
for HEp-2 cells similar to those found for Pmp21-PD.
Interestingly, even small domains of only 50 amino acids
(e.g. Pmp21-BD2) display undiminished adhesion. Curi-
ously, the adhesive capacity of Pmp21-E and -G is not
signiﬁcantly enhanced relative to that of the smaller
fragments. The presence of multiple binding sites on
N-Pmp21 and M-Pmp21 could allow them to engage
several receptor molecules, or several binding sites on a
single receptor molecule simultaneously. We can exclude
polymeric glycosaminoglycan structures on HEp-2 cells
as potential Pmp21 receptors, as yeast cells presenting
Pmp21-B or -D adhered equally well to GAG-deﬁcient
CHO lines and the control line K1 (data not shown). GAGs
are required for binding of OmcB adhesin, however
(Moelleken and Hegemann, 2008), although it is not clear
how the activity of OmcB and the Pmp adhesins is
co-ordinated during adhesion.
All Pmp21 domains tested showed signiﬁcant adhesion
to HEp-2 cells, while their ability to inhibit infection varied.
Pmp21 variants resembling the natural processed forms
were most effective, suggesting that these present
optimal binding conformations to the receptor(s). This
may also explain why the Pmp21-derived peptide had
only moderate infection-blocking activity. The inhibitory
effect of soluble recombinant Pmp21 protein was con-
ﬁrmed by the neutralizing activity of anti-Pmp21-E anti-
bodies, in agreement with published data for N-Pmp21
and PmpD from C. trachomatis (Wehrl et al., 2004; Crane
et al., 2006). Recombinant Pmp6 and rPmp20 also exhib-
ited adhesion to epithelial cells, reduced binding of infec-
tious EBs to HEp-2 cells, and blocked subsequent
infection (Figs 6B and C and 7A). Unlike Pmp6, Pmp20
showed a dose dependence similar to Pmp21. This sug-
gests that binding of human cells might vary with Pmp
subtype.
All Pmps have multiple copies of the motifs FxxN and
GGA(I, L, V) in their N-terminal segments (Grimwood
and Stephens, 1999). We found that adhesion of all
Pmp21 domains tested required a minimum of two
copies of these motifs [2x FxxN or FxxN plus GGA(I, L,
V)]. We did not test whether two copies of the GGA(I, L,
V) motif are sufficient for adhesion. The distribution of
these motifs in Pmps shows no obvious pattern, but the
two types often occur as doublets of the form FxxN-x5–
17-GGA(I, L, V). Indeed, a small M-Pmp21 fragment with
a typical doublet (FxxN-x8-GGAI) exhibited adhesion and
interfered with infection by C. pneumoniae (Fig. 5D). The
motifs may be required for maintenance of the Pmp con-
formation that permits adhesion, or might directly
mediate interaction with human receptors, or both. Alter-
natively, the wide variation in the number and spacing of
the two motifs could provide a surface unique for each
individual Pmp. Repeats of short sequences have been
described for other adhesive autotransporters, but no
function has been attributed to them (Girard and
Mourez, 2006).
Our data show that Pmp6, Pmp20 and Pmp21, repre-
senting three of the six Pmp subtypes (G, B/C and D
respectively), exhibit very similar functional properties
(adhesion, partial inhibition of EB binding to human cells,
blockage of subsequent infection). These observations
suggest that they have similar or even overlapping
functions. In agreement with this, we found that pre-
incubation of HEp-2 cells with two different Pmp proteins
(rPmp6-1 and rPmp21-E) in a single experiment signiﬁ-
cantly reduced infection, under conditions where each
protein alone was ineffective (Fig. 7B). These preliminary
data are concordant with a hypothetical model, in which
Pmp6 and Pmp21 have similar but non-redundant roles
during adhesion and invasion, possibly recognizing the
same host cell receptor or a group of related receptors.
We have preliminary data that Pmp20 also participates in
this functional network (data not shown). Pmp6 belongs to
subtype G, which comprises 13 members in C. pneumo-
niae (Grimwood and Stephens, 1999). Other Pmps of this
subtype might have similar roles in infection, as at least
nine are reported to be present on infectious EBs
(Vandahl et al., 2001; Montigiani et al., 2002). Indeed,
several, or perhaps all, expressed Pmps might together
form a supramolecular complex that is required for effi-
cient adhesion. Anti-Pmp21 does not cross-react with
Pmp6 or Pmp20 in Western blots (data not shown);
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pneumoniae. If these three Pmps were involved in a mul-
timeric complex on the bacterial cell surface, an antibody
against anyone could conceivably block adhesion medi-
ated by the others. Indeed, studies in C. trachomatis and
C. psittaci suggest that Pmp PDs could perform homo- or
hetero-oligomeric interactions with other Pmps (Tanzer
et al., 2001; Swanson et al., 2009). Those interactions
could be modulated by host cell enzymes, e.g. by protein
disulphide isomerase (PDI), a surface-located host
protein, which is necessary for EB entry (Abromaitis and
Stephens, 2009).
The diversity of the Pmp superfamily may also be attrib-
utable to antigenic variation as in the case of the Opa
protein family in Neisseria gonorrhoeae (Grimwood and
Stephens, 1999; Carbonnelle et al., 2009). This could
compromise the host’s ability to mount a potent humoral
immune response and thus disable host defence
mechanisms. This idea is supported by the important
ﬁnding that Pmp10 from C. pneumoniae, as well as all
nine Pmps (including the Pmp21 homologue PmpD) in C.
trachomatis, are variably expressed in inclusions formed
in cultured cells (Pedersen et al., 2001; Tan et al., 2010).
This may explain why sera from C. trachomatis-infected
patients show signiﬁcant differences in Pmp-speciﬁc anti-
body proﬁles (Tan et al., 2009). If the expression of Pmps
on the EB surface also varies in C. pneumoniae, the pool
of 21 Pmp proteins could form the basis for broad anti-
genic diversity, while ensuring that EB adhesion proper-
ties remain stable.
Pmp proteins may function in concert with other EB
surface proteins. For example, the C. trachomatis PmpD
seems to be in close contact with serovariable MOMP and
LPS, as antibodies against either block neutralization by
PmpD antibodies, suggesting a decoy-like immune
evasion strategy (Crane et al., 2006). Likewise, in C.
pneumoniae Pmp10 apparently protects the C-terminal
part of MOMP from proteolytic cleavage (Juul et al.,
2007). While for the C. trachomatis MOMP unspeciﬁc
interactions with host cells have been proposed (Su et al.,
1990), we could not detect adhesion of recombinant C.
pneumoniae MOMP to HEp-2 cells, possibly due to lack of
the post-translational modiﬁcations that have been found
in native C. psittaci and C. trachomatis MOMPs (summa-
rized in Campbell and Kuo, 2006).
Safe recombinant vaccines, based on a small number
of antigenic proteins, are emerging as the most cost-
effective way of combating infectious diseases. Adhesins
are interesting vaccine candidates, as some provide pro-
tection against infection in animal models (Kline et al.,
2009). A combination of Pmp proteins could yield a very
effective vaccine, and would minimize problems associ-
ated with antigenic variation that may be linked with this
class of proteins.
Experimental procedures
Bacterial strains, yeast strains and culture conditions
Escherichia coli strain XL-1 blue (Stratagene) was used for
protein expression and plasmid ampliﬁcation. C. pneumoniae
GiD was propagated in HEp-2 cells (ATCC No. CCL-23) as
described (Jantos et al., 1997). Chlamydial EBs were puriﬁed
by using a 30% gastrographin gradient (Schering). The Sac-
charomyces cerevisiae strain yEG2 (MATa ura3-52 trp1
LEU2 his3D200 pep4:HIS3 prb1D.6R can1 GAL1p-
AGA1::pIU211 leu2D1::pCM149) was used for yeast display
experiments: the GAL1 promoter of the chromosomally inte-
grated GAL1p-AGA1 expression unit in strain EBY100 (Invit-
rogen) was substituted for the KanMX-tetO7-CYC1p promoter
by PCR-based homologous recombination using plasmid
pAH3. Strain yEG2 was routinely grown in selective synthetic
dextrose (SD) medium plus 2% glucose (Sherman, 1991).
DNA manipulations and plasmid construction
Plasmids were generated in S. cerevisiae as described
(Moelleken and Hegemann, 2008). The yeast expression
vector pEG2 (this work) was generated by replacing the
GAL1 promoter in pYD1 (Invitrogen) with the tetO7-CYC1
promoter ampliﬁed by PCR from pCM189 (Gari et al., 1997).
The E. coli expression vector pKM32 (this work) was con-
structed by integration of a CEN6 ARS4 URA3 cassette into
XbaI/PvuII-linearized pQE-31 (Qiagen). The pmp21 variants
were ampliﬁed by PCR using C. pneumoniae GiD DNA as
template, and cloned into NotI-digested pEG vector or fused
N-terminally to a His6-Tag and cloned into the SmaI site in
pKM32. Pmp6 or pmp20 variants and the Y. pseudotubercu-
losis sequence encoding the invasin fragments Inv197 (aa
772–969) and Inv497 (aa 490–969) subcloned from pRI285
(Dersch and Isberg, 1999) were cloned into pKM32 as
described above. Plasmid pYD1-Inv197 has been described
before (Moelleken and Hegemann, 2008). Site-speciﬁc
mutagenesis was performed using oligonucleotides. All con-
structs were sequenced prior to use.
Protein expression and affinity puriﬁcation of
His6-tagged proteins
For expression of Aga2p or Aga2p fusion proteins in yEG2,
cells were grown in selective SD medium and harvested in
logarithmic phase. Expression and puriﬁcation of His6-tagged
fusion proteins was performed under denaturing conditions
following the manufacturer’s instructions (Qiagen). Proteins
were renatured by dialysis against PBS, and detected after
SDS-PAGE by Western analysis with an anti-His antibody
(Qiagen).
Immunoblot analysis
SDS-PAGE and immunoblot analysis were performed as
described (Moelleken and Hegemann, 2008). For detection
of Pmp216His proteins, monoclonal anti-His antibodies
(Qiagen) or a polyclonal anti-Pmp21-E serum (antigen-
puriﬁed; IgG 87 mgm l
-1) (1:250 dilution) was used and
visualized with AP-conjugated anti-mouse or anti-rabbit
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cells were infected with C. pneumoniae at moi 1. After
12–96 h cells were prepared and analysed by SDS-PAGE
using a monoclonal anti-b-actin antibody or anti-Pmp21-E
serum (antigen-puriﬁed). EBs were gradient-puriﬁed after
72 h p.i., and 1 ¥ 10
7 EBs were resuspended in PBS, or in
PBS with 2% Sarcosyl, 2% SDS, 10 mM DTT, and sonicated
for 1 min at room temperature (RT). Loading dye and 1 mM
DTT were added and samples were boiled for 10 min at
100°C. Prior to loading, samples were pelleted for 1 min at
13 000 r.p.m. and supernatant was loaded. Proteins were
detected by the anti-Pmp21-E serum (antigen-puriﬁed).
Immunoﬂuorescence microscopy
Twenty-four to 90 h p.i. HEp-2 cells on glass coverslips
(12 mm diameter) were washed once with PBS, ﬁxed with
freshly prepared 3% formaldehyde (diluted from a 30% form-
aldehyde stock solution, which was prepared by dissolving
paraformaldehyde powder in PBS at 65°C) for 30 min at RT
and permeabilized with PBS containing 0.2% Triton X-100 or
ﬁxed with 96% methanol for 10 min at RT (Vandahl et al.,
2002). The monolayer was washed three times with PBS. For
detection of chlamydial inclusions or non-ﬁxed C. pneumo-
niae EBs, either anti-DnaK (Birkelund et al., 1990), anti-
OmpA (Dako) or anti-Pmp21-E serum (antigen puriﬁed; IgG
87 mgm l
-1) (undiluted) was used in combination with Cy3-
conjugated anti-mouse antibody (Sigma) or FITC-conjugated
anti-rabbit antibody (Dako). For direct staining of inclusions, a
monoclonal FITC-conjugated antibody against chlamydial
LPS was used (Bio-Rad). Cells were viewed using a Zeiss
Axioskop. The microimmunoﬂuorescence (MIF) analysis was
performed as described (Moelleken and Hegemann, 2008).
Yeast cell staining
Approximately 5 ¥ 10
6 yeast cells from 24 h cultures were
washed twice with PBS and immobilized on poly-L-lysine-
coated glass slides. Slides were incubated with PBS contain-
ing 1% BSA followed by incubation with anti-V5 and Cy3-
conjugated anti-mouse antibodies (Invitrogen, Sigma).
Adhesion assays
Yeast adhesion assays were performed with HEp-2 cells as
previously described (Moelleken and Hegemann, 2008).
Adhesion assays with protein-coated latex beads were per-
formed as described (Dersch and Isberg, 1999).Alternatively,
bead binding to HEp-2 cells was quantiﬁed by ﬂow cytometry.
HEp-2 cells were grown to a conﬂuent monolayer in 24-well
plates and incubated with a 10-fold excess of protein-coated
latex beads (diameter 1 mm, green ﬂuorescent, Sigma) for 1 h
at 37°C. Cells were washed twice with PBS, detached with
Cell Dissociation solution (Sigma) and analysed by ﬂow
cytometry using a FACSAria (BD Biosciences).
Infection inhibition assays
These assays were performed as previously described
(Moelleken and Hegemann, 2008). The anti-Pmp21-E serum
(total protein content 3 mg ml
-1) was used without further
puriﬁcation as outlined in the legend of Fig. 5A. Statistical
analysis of the infection inhibition assay was carried out by
Student’s t-test.
Flow cytometric assay for adhesion of CFSE-labelled
C. pneumoniae EBs
Approximately 2 ¥ 10
8 puriﬁed C. pneumoniae EBs were
labelled for 1 h at 37°C with 25 mmol of CFSE (Molecular
Probes) and washed twice with PBS containing 1% BSA as
previously described (Schnitger et al., 2007). Conﬂuent
monolayers of HEp-2 cells grown in 24-well plates were incu-
bated for 4 h at 37°C with 12.5–200 mgm l
-1 recombinant
protein or 500 mgm l
-1 heparin, CFSE-labelled C. pneumo-
niae EBs (moi 10) were added for 1 h. Cells were then
washed with PBS, trypsinized and ﬁxed with formaldehyde,
and the efficiency of adhesion was measured by ﬂow cytom-
etry using a FACSAria (BD Biosciences).
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